Douglass Winthrop Advisors LLC Buys 6,816 Shares of Pfizer Inc. (NYSE:PFE)

Douglass Winthrop Advisors LLC boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 16.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 48,123 shares of the biopharmaceutical company’s stock after buying an additional 6,816 shares during the period. Douglass Winthrop Advisors LLC’s holdings in Pfizer were worth $1,393,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in PFE. Fisher Asset Management LLC increased its holdings in shares of Pfizer by 226.7% during the third quarter. Fisher Asset Management LLC now owns 6,209,907 shares of the biopharmaceutical company’s stock valued at $179,715,000 after acquiring an additional 4,309,076 shares in the last quarter. Daiwa Securities Group Inc. increased its stake in Pfizer by 25.9% during the 3rd quarter. Daiwa Securities Group Inc. now owns 804,522 shares of the biopharmaceutical company’s stock valued at $23,283,000 after purchasing an additional 165,611 shares in the last quarter. Marco Investment Management LLC raised its holdings in Pfizer by 3.6% in the third quarter. Marco Investment Management LLC now owns 148,432 shares of the biopharmaceutical company’s stock worth $4,296,000 after buying an additional 5,100 shares during the last quarter. Hartford Funds Management Co LLC lifted its stake in shares of Pfizer by 5.7% in the third quarter. Hartford Funds Management Co LLC now owns 31,832 shares of the biopharmaceutical company’s stock worth $921,000 after buying an additional 1,716 shares in the last quarter. Finally, Pekin Hardy Strauss Inc. grew its holdings in shares of Pfizer by 3.0% during the third quarter. Pekin Hardy Strauss Inc. now owns 27,895 shares of the biopharmaceutical company’s stock valued at $807,000 after buying an additional 800 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 2.1 %

PFE opened at $25.65 on Monday. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The firm’s 50 day simple moving average is $28.21 and its two-hundred day simple moving average is $28.57. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $145.36 billion, a PE ratio of 34.66, a PEG ratio of 0.82 and a beta of 0.67.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. Pfizer’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.17) earnings per share. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 6.55%. The ex-dividend date is Friday, November 8th. Pfizer’s payout ratio is 227.03%.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the stock in a transaction dated Wednesday, October 30th. The shares were acquired at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. The trade was a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 0.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on PFE shares. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Wells Fargo & Company upped their price target on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Sanford C. Bernstein started coverage on Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective for the company. UBS Group upped their target price on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Finally, Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $32.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.